SupplyCopia's participation at AHRMM25 builds on the company's continued commitment to transforming healthcare supply chains through innovative AI solutions. The company's technology has helped health ...

Executive officers and members of Tevogen’s Board of Directors collectively hold over 74% of the Company’s outstanding shares. This substantial insider ownership reflects the leadership’s deep ...

FAITS SAILLANTS La généreuse contribution de la Fondation de la famille Slaight permettra à la Croix-Rouge d’offrir un soutien humanitaire aux personnes déplacées du Myanmar, en particulier les femmes ...

Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of ...

The Canadian Red Cross extends its gratitude to Gary Slaight and The Slaight Family Foundation for a $1 million contribution over two years, in support of humanitarian efforts in Cox’s Bazar, ...

These two clearances mark an important step forward for Bioventus and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be ...

A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at ...

“This partnership reflects our mutual commitment to advancing precision medicine for cancer,” said Dr. Bo Du, CEO of Genecast. “By integrating Paragon’s world-class target enrichment technologies into ...

LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only ...

About BioNexus Gene Lab Corp. BGLC is an innovation-led life-sciences platform – bringing together precision diagnostics, cross-border expertise, and AI data development. Listed on Nasdaq, BGLC’s ...

Preclinical data presented at SAWC, the largest wound care conference in the United States, highlighted the in vitro performance of revyve ®, including inhibition of key proteases such as matrix ...

Title: Results from a Phase 1 expansion cohort of solnerstotug (pH-selective anti-VISTA antibody) combined with cemiplimab in patients with advanced solid tumors resistant to prior PD- (L)1 therapy ...